share_log

Viking Therapeutics | 10-Q: Q3 2024 Earnings Report

Viking Therapeutics | 10-Q: Q3 2024 Earnings Report

Viking Therapeutics | 10-Q：2024財年三季報
美股SEC公告 ·  10/24 05:05

Moomoo AI 已提取核心訊息

Viking Therapeutics reported financial results for Q3 2024, with research and development expenses increasing 24% to $22.8 million compared to Q3 2023. The rise was primarily due to higher manufacturing costs, stock-based compensation, and salaries. General and administrative expenses grew 55% to $13.8 million, driven by increased stock-based compensation and legal services.The company's cash position remained strong at $930.4 million as of September 30, 2024, expected to fund operations through at least December 2025. Viking completed a public offering in March 2024, raising net proceeds of $597.1 million. The company also continued its at-the-market (ATM) offering program, with the ability to raise up to $151.9 million in additional funds.Viking's clinical programs progressed, with positive results reported from the Phase 2 VENTURE study of VK2735 for obesity and the Phase 2b VOYAGE study of VK2809 for MASH/NASH. The company plans to advance subcutaneous VK2735 into Phase 3 development for obesity and initiate a Phase 2 trial with the oral formulation later in 2024.
Viking Therapeutics reported financial results for Q3 2024, with research and development expenses increasing 24% to $22.8 million compared to Q3 2023. The rise was primarily due to higher manufacturing costs, stock-based compensation, and salaries. General and administrative expenses grew 55% to $13.8 million, driven by increased stock-based compensation and legal services.The company's cash position remained strong at $930.4 million as of September 30, 2024, expected to fund operations through at least December 2025. Viking completed a public offering in March 2024, raising net proceeds of $597.1 million. The company also continued its at-the-market (ATM) offering program, with the ability to raise up to $151.9 million in additional funds.Viking's clinical programs progressed, with positive results reported from the Phase 2 VENTURE study of VK2735 for obesity and the Phase 2b VOYAGE study of VK2809 for MASH/NASH. The company plans to advance subcutaneous VK2735 into Phase 3 development for obesity and initiate a Phase 2 trial with the oral formulation later in 2024.
Viking Therapeutics公佈了2024年第三季度的財務結果，與2023年第三季度相比，研究和開發費用增加了24%，達2280萬美元。增長主要是由於製造業成本、基於股票的補償和薪資的增加。管理費用增長了55%，達到1380萬美元，主要是由於基於股票的補償和法律服務的增加。截至2024年9月30日，公司現金狀況依然強勁，達93040萬美元，預計可支持運營至少到2025年12月。Viking於2024年3月完成了一次公開募股，籌集到淨收益59710萬美元。公司還繼續其市場上的（ATM）發售計劃，能夠額外籌集至多15190萬美元的所有基金類型。Viking的臨牀項目進展順利，報告了VK2735針對肥胖的第二階段創業公司的正面結果以及VK2809針對MASH/NASH的第二十階段VOYAGE研究的結果。公司計劃將VK2735推進至肥胖的第三階段開發，並在2024年晚些時候啓動口服配方的第二階段試驗。
Viking Therapeutics公佈了2024年第三季度的財務結果，與2023年第三季度相比，研究和開發費用增加了24%，達2280萬美元。增長主要是由於製造業成本、基於股票的補償和薪資的增加。管理費用增長了55%，達到1380萬美元，主要是由於基於股票的補償和法律服務的增加。截至2024年9月30日，公司現金狀況依然強勁，達93040萬美元，預計可支持運營至少到2025年12月。Viking於2024年3月完成了一次公開募股，籌集到淨收益59710萬美元。公司還繼續其市場上的（ATM）發售計劃，能夠額外籌集至多15190萬美元的所有基金類型。Viking的臨牀項目進展順利，報告了VK2735針對肥胖的第二階段創業公司的正面結果以及VK2809針對MASH/NASH的第二十階段VOYAGE研究的結果。公司計劃將VK2735推進至肥胖的第三階段開發，並在2024年晚些時候啓動口服配方的第二階段試驗。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間